| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1051059730 |
| P356 | DOI | 10.1186/2162-3619-1-3 |
| P932 | PMC publication ID | 3506991 |
| P698 | PubMed publication ID | 23210632 |
| P5875 | ResearchGate publication ID | 233847588 |
| P2093 | author name string | Delong Liu | |
| Karen Seiter | |||
| Guoqing Wei | |||
| Gustavo Cadavid | |||
| Asim Ajaz | |||
| Uzoma Nwakuche | |||
| P2860 | cites work | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 |
| Current management and novel agents for malignant melanoma | Q37983934 | ||
| Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). | Q51800094 | ||
| P433 | issue | 1 | |
| P921 | main subject | metastatic melanoma | Q18975855 |
| ipilimumab | Q2459042 | ||
| P304 | page(s) | 3 | |
| P577 | publication date | 2012-03-26 | |
| P1433 | published in | Experimental Hematology & Oncology | Q23979095 |
| P1476 | title | Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma | |
| P478 | volume | 1 |
| Q91928619 | Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect |
| Q89526156 | Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events |
| Q64085283 | Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia |
| Q38893697 | Ipilimumab in melanoma |
| Q42357541 | Ipilimumab-Induced Neutropenia in Melanoma |
| Q31034415 | Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper |
| Q33877109 | Serious haematological toxicity during and after ipilimumab treatment: a case series. |
Search more.